STOCK TITAN

Processa Pharmaceuticals Inc - PCSA STOCK NEWS

Welcome to our dedicated news page for Processa Pharmaceuticals (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Processa Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Processa Pharmaceuticals's position in the market.

Rhea-AI Summary
Processa Pharmaceuticals provides interim analysis of Phase 1B trial for NGC-Cap chemotherapy treatment. Personalized dosing regimen shows potential to improve safety and efficacy. Currently, capecitabine is dosed universally, leading to reduced efficacy and side effects. Early results are encouraging.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.82%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.88%
Tags
management
Rhea-AI Summary
Processa Pharmaceuticals CEO, Dr. David Young, to present at MedInvest Oncology Investor Conference on June 21-22, 2023 in Boston.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
conferences
-
Rhea-AI Summary
Processa Pharmaceuticals has received guidance from the FDA for its next trial for Next Generation Chemotherapy-Capecitabine (NGC-Cap). The trial will be a Phase 2 safety-efficacy trial in colorectal cancer patients, following FDA's Project Optimus Oncology Initiative. NGC-Cap is designed to decrease side effects while increasing exposure to cancer-killing molecules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.55%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.54%
Tags
none
Processa Pharmaceuticals Inc

Nasdaq:PCSA

PCSA Rankings

PCSA Stock Data

4.04M
969.87k
15.06%
2.59%
2.36%
Heavy Duty Truck Manufacturing
Manufacturing
Link
United States
Hanover

About PCSA

processa pharmaceuticals was founded in october 2017 with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. the company is headquartered in hanover, maryland.